Skip to content
Logo
  • Solutions
    Solutions
    • R&D Teams
    • Regulatory Teams
    • Commercial Teams
    • HEOR Teams
    • Cancer Centers and Oncologists
  • Products
    Products
    • Focus
    • Vantage
    • Vista
    • Clinicogenomics
    • Real-World Analytics
  • Services
    Services
    • Real-World Insights & Support
  • About Us
    About Us
    • Our Mission
    • Careers
  • Resources
    Resources
    • Research
    • Blog
    • News
    • Podcasts
    • Case Studies

    Sounds of Support: COTA & Friends Unite for Young Adults with Cancer

    Read More

    Extending COTA’s global reach with RWD in oncology research

    Read More
Contact Us

Type: Poster

Colorectal cancer care disparities in an urban diverse population: A tale of two hospitals in the nation’s capital.

Identifying Fit-for-Emulation Data: Adaptation of a Structured Data Feasibility Assessment Process for Real-World Oncology Trial Emulations

P2-06-22: PreciseBreast, an AI-enabled digital test predicting breast cancer recurrence is equivalent with Oncotype in an observational, retrospective study of patients from Baptist Health Miami Cancer Institute in partnership with COTA, Inc.

Trends in All-Cause Mortality Rates in Patients with Follicular Lymphoma in the US before and during the COVID-19 Pandemic: A Retrospective Observational Study

An Indirect Comparison of Elranatamab’s Progression-Free Survival, Duration of Response, and Overall Survival from MagnetisMM-3 Versus Real-World External Control Arms in Triple-Class Refractory Multiple Myeloma

Impact of the Diagnosis-to-Treatment Interval (DTI) on Outcomes in Older Adults with Diffuse Large B-Cell Lymphoma (DLBCL) Treated in the Real-World Setting

End-of-Life Care Patterns in Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in the Real-World Setting

P3-03-20: A multicenter retrospective review of clinical-pathological characteristics associated with survival outcomes in a large cohort of metaplastic breast cancer patients

656P Real-World (RW) frontline (1L) treatments (Txs) in patients (Pts) with advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EFGR) exon 20 insertions (exon20ins) and adjusted comparisons versus PAPILLON study

1346P A population-level prognostic score model for early acquired resistance to frontline anti-PD-(L)1 therapy in metastatic non-small cell lung cancer (NSCLC)

Next →
Logo
footer-background
Solutions
  • R&D Teams
  • Regulatory Teams
  • Commercial Teams
  • HEOR Teams
  • Oncology Providers
Products & Services
  • Focus
  • Vantage
  • Vista
  • Clinicogenomics
  • Real-World Analytics
  • Real-World Insights & Support
About Us
  • Our Mission
  • Careers
  • Become a Data Partner
Follow Us
  • LinkedIn
  • Real World Talk with COTA
  • Real World Talk with COTA
© 2025 COTA. All rights reserved.
  • Privacy Policy
  • Terms of Service
  • CCPA Privacy Notice